These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28978927)

  • 1. Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia.
    Sato S; Zamami Y; Imai T; Tanaka S; Koyama T; Niimura T; Chuma M; Koga T; Takechi K; Kurata Y; Kondo Y; Izawa-Ishizawa Y; Sendo T; Nakura H; Ishizawa K
    Sci Rep; 2017 Oct; 7(1):12683. PubMed ID: 28978927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients.
    Amino M; Yoshioka K; Opthof T; Morita S; Uemura S; Tamura K; Fukushima T; Higami S; Otsuka H; Akieda K; Shima M; Fujibayashi D; Hashida T; Inokuchi S; Kodama I; Tanabe T
    J Cardiovasc Pharmacol; 2010 Apr; 55(4):391-8. PubMed ID: 20147846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia.
    Shiga T; Tanaka K; Kato R; Amino M; Matsudo Y; Honda T; Sagara K; Takahashi A; Katoh T; Urashima M; Ogawa S; Takano T; Kasanuki H;
    Resuscitation; 2010 Jan; 81(1):47-52. PubMed ID: 19913983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug Therapy for Shock-Resistant Ventricular Fibrillation: Comparison of Nifekalant and Amiodarone].
    Harayama N; Nihei S; Nagata K; Aibara K; Kamochi M; Sata T
    J UOEH; 2016 Mar; 38(1):35-46. PubMed ID: 26972943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifekalant Hydrochloride and Amiodarone Hydrochloride Result in Similar Improvements for 24-Hour Survival in Cardiopulmonary Arrest Patients: The SOS-KANTO 2012 Study.
    Amino M; Inokuchi S; Nagao K; Nakagawa Y; Yoshioka K; Ikari Y; Funakoshi H; Hayakawa K; Matsuzaki M; Sakurai A; Tahara Y; Yonemoto N; Yaguchi A; Morimura N;
    J Cardiovasc Pharmacol; 2015 Dec; 66(6):600-9. PubMed ID: 26317166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest.
    Tagami T; Matsui H; Ishinokami S; Oyanagi M; Kitahashi A; Fukuda R; Unemoto K; Fushimi K; Yasunaga H
    Resuscitation; 2016 Dec; 109():127-132. PubMed ID: 27568110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation.
    Valdes SO; Donoghue AJ; Hoyme DB; Hammond R; Berg MD; Berg RA; Samson RA;
    Resuscitation; 2014 Mar; 85(3):381-6. PubMed ID: 24361455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation.
    Harayama N; Nihei S; Nagata K; Isa Y; Goto K; Aibara K; Kamochi M; Sata T
    J Anesth; 2014 Aug; 28(4):587-92. PubMed ID: 24389941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes associated with amiodarone and lidocaine for the treatment of adult in-hospital cardiac arrest with shock-refractory pulseless ventricular tachyarrhythmia.
    Wang CH; Chang WT; Huang CH; Tsai MS; Yu PH; Wu YW; Liu YB; Chen WJ
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):327-334. PubMed ID: 31255419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do not consider amiodarone, give it! Comment on antiarrhythmic drugs for shock‑refractory ventricular fibrillation or pulseless ventricular tachycardia.
    Gibson AE; Jaeschke R
    Pol Arch Med Wewn; 2016 Oct; 126(10):791-792. PubMed ID: 27872454
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome.
    Yusu S; Ikeda T; Mera H; Miyakoshi M; Miwa Y; Abe A; Tsukada T; Ishiguro H; Shimizu H; Yoshino H
    Circ J; 2009 Nov; 73(11):2021-8. PubMed ID: 19724153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
    Kudenchuk PJ; Brown SP; Daya M; Rea T; Nichol G; Morrison LJ; Leroux B; Vaillancourt C; Wittwer L; Callaway CW; Christenson J; Egan D; Ornato JP; Weisfeldt ML; Stiell IG; Idris AH; Aufderheide TP; Dunford JV; Colella MR; Vilke GM; Brienza AM; Desvigne-Nickens P; Gray PC; Gray R; Seals N; Straight R; Dorian P;
    N Engl J Med; 2016 May; 374(18):1711-22. PubMed ID: 27043165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction.
    Piccini JP; Schulte PJ; Pieper KS; Mehta RH; White HD; Van de Werf F; Ardissino D; Califf RM; Granger CB; Ohman EM; Alexander JH
    Crit Care Med; 2011 Jan; 39(1):78-83. PubMed ID: 20959785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amiodarone: an emergency medicine perspective.
    Taylor SE
    Emerg Med (Fremantle); 2002 Dec; 14(4):422-9. PubMed ID: 12534486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of Nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest].
    Amino M; Yoshioka K; Iwata O; Fujikura H; Deguchi Y; Ban K; Shiina Y; Goto S; Handa S; Tanabe T; Nakagawa Y; Morita S; Iwase H; Yamamoto I; Inokuchi S; Marutani Y
    J Cardiol; 2003 Mar; 41(3):127-34. PubMed ID: 12674997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing intravenous amiodarone or lidocaine, or both, outcomes for inpatients with pulseless ventricular arrhythmias.
    Rea RS; Kane-Gill SL; Rudis MI; Seybert AL; Oyen LJ; Ou NN; Stauss JL; Kirisci L; Idrees U; Henderson SO
    Crit Care Med; 2006 Jun; 34(6):1617-23. PubMed ID: 16614583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amiodarone, lidocaine, magnesium or placebo in shock refractory ventricular arrhythmia: A Bayesian network meta-analysis.
    Khan SU; Winnicka L; Saleem MA; Rahman H; Rehman N
    Heart Lung; 2017; 46(6):417-424. PubMed ID: 28958592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease.
    Ando J; Kakishita M; Sakai K; Komura Y; Nishiyama K; Iwabuchi M; Yokoi H; Yasumoto H; Nosaka H; Nobuyoshi M
    Int Heart J; 2005 Jul; 46(4):647-56. PubMed ID: 16157956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation.
    Karlis G; Iacovidou N; Lelovas P; Niforopoulou P; Papalois A; Siafaka I; Mentzelopoulos S; Xanthos T
    Cardiovasc Drugs Ther; 2015; 29(5):425-31. PubMed ID: 26145169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents--focus on amiodarone.
    Scheinman MM
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):914-9. PubMed ID: 8548112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.